The human potential of a recombinant pandemic influenza vaccine produced in tobacco plants

Human Vaccines and Immunotherapeutics

Volumn 8, Issue 5, 2012, Pages 653-661

  Jul Larsen, Asne ^a   Madhun, Abdullah S ^a   Brokstad, Karl A ^a   Montomoli, Emanuele ^b   Yusibov, Vidadi ^c   Cox, Rebecca J ^a,d  

^a UNIVERSITY OF BERGEN   (Norway)

^b UNIVERSITY OF SIENA   (Italy)

^c Fraunhofer USA Inc   (United States)

^d HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

B cell; Haemagglutinin; HI; Human; Influenza; Plant based; Recombinant antigen; SRH; T cell; Vaccine

Indexed keywords

GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; INFLUENZA VACCINE; INFLUENZA VIRUS A H1N1 ANTIBODY; INFLUENZA VIRUS HEMAGGLUTININ; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 2; INTERLEUKIN 5; RECOMBINANT ANTIGEN; RECOMBINANT INFLUENZA HEMAGGLUTININ ANTIGEN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VIRUS ANTIBODY;

2009 H1N1 INFLUENZA; ADULT; ANTIBODY RESPONSE; ANTIGEN EXPRESSION; ANTIGEN RECOGNITION; ARTICLE; B LYMPHOCYTE; BLOOD SAMPLING; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL INTERACTION; CELL STIMULATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DISEASE SEVERITY; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; FATIGUE; FEMALE; FUNCTION TEST; HEALTH CARE PERSONNEL; HEMAGGLUTINATION INHIBITION TEST; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; IMMUNOGENICITY; IN VITRO STUDY; INFLUENZA VIRUS A H1N1; INJECTION SITE PAIN; LYMPHOCYTE; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN EXPRESSION; SINGLE RADIAL HEMOLYSIS; TH1 CELL; TOBACCO; VACCINE PRODUCTION;

ADULT; ANTIBODIES, VIRAL; B-LYMPHOCYTES; CD4-POSITIVE T-LYMPHOCYTES; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; ENZYME-LINKED IMMUNOSPOT ASSAY; FEMALE; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMAN EXPERIMENTATION; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; PLANTS, GENETICALLY MODIFIED; TH1 CELLS; TIME FACTORS; TOBACCO; VACCINES, SYNTHETIC;

EID: 84863645839     PISSN: None     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.19503     Document Type: Article

References (48)

1. Chichester JA, Yusibov V. Plants as alternative systems for production of vaccines. Hum Vaccin 2007; 3:146-8; PMID: 17643065; DOI: 10.4161/hv.3.4.4148.
2. Chichester JA, Haaheim LR, Yusibov V. Using plant cells as influenza vaccine substrates. Expert Rev Vaccines 2009; 8:493-8; PMID: 19348564; DOI: 10.1586/erv.09.3.
3. Shoji Y, Chichester JA, Jones M, Manceva SD, Damon E, Mett V, et al. Plant-based rapid production of recombinant subunit hemagglutinin vaccines targeting H1N1 and H5N1 influenza. Hum Vaccin 2011; 7:41-50; PMID: 21266846; DOI: 10.4161/hv.7.0.14561.
4. Lu X, Tumpey TM, Morken T, Zaki SR, Cox NJ, Katz JM. A mouse model for the evaluation of pathogenesis and immunity to influenza A (H5N1) viruses isolated from humans. J Virol 1999; 73:5903-11; PMID: 10364342.
5. Lipatov AS, Hoffmann E, Salomon R, Yen H-L, Webster RG. Cross-protectiveness and immunogenicity of influenza A/Duck/Singapore/3/97(H5) vaccines against infection with A/Vietnam/1203/04(H5N1) virus in ferrets. J Infect Dis 2006; 194:1040- 3; PMID: 16991078; DOI: 10.1086/507709.
6. Treanor JJ, Wilkinson BE, Masseoud F, Hu-Primmer J, Battaglia R, O'Brien D, et al. Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans. Vaccine 2001; 19:1732-7; PMID: 11166898; DOI: 10.1016/S0264-410X(00)00395-9.
7. Nicholson KG, Colegate AE, Podda A, Stephenson I, Wood J, Ypma E, et al. Safety and antigenicity of non-adjuvanted and MF59- adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza. Lancet 2001; 357:1937-43; PMID: 11425416; DOI: 10.1016/S0140-6736(00)05066-2.
8. Zhu F-C, Wang H, Fang H-H, Yang JG, Lin XJ, Liang X-F, et al. A novel influenza A (H1N1) vaccine in various age groups. N Engl J Med 2009; 361:2414-23; PMID: 19846844; DOI: 10.1056/NEJMoa0908535.
9. Liang X-F, Wang H-Q, Wang J-Z, Fang H-H, Wu J, Zhu F-C, et al. Safety and immunogenicity of 2009 pandemic influenza A H1N1 vaccines in China: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet 2010; 375:56-66; PMID: 20018364; DOI: 10.1016/S0140-6736(09)62003-1.
10. Greenberg ME, Lai MH, Hartel GF, Wichems CH, Gittleson C, Bennet J, et al. Response to a monovalent 2009 influenza A (H1N1) vaccine. N Engl J Med 2009; 361:2405-13; PMID: 19745216; DOI: 10.1056/NEJMoa0907413.
11. Plennevaux E, Sheldon E, Blatter M, Reeves-Hoché M-K, Denis M. Immune response after a single vaccination against 2009 influenza A H1N1 in USA: a preliminary report of two randomised controlled phase 2 trials. Lancet 2010; 375:41-8; PMID: 20018365; DOI: 10.1016/S0140-6736(09)62026-2.
12. Clark TW, Pareek M, Hoschler K, Dillon H, Nicholson KG, Groth N, et al. Trial of 2009 influenza A (H1N1) monovalent MF59- adjuvanted vaccine. N Engl J Med 2009; 361:2424-35; PMID: 19745215; DOI: 10.1056/NEJMoa0907650.
13. Madhun AS, Akselsen PE, Sjursen H, Pedersen G, Svindland S, Nøstbakken JK, et al. An adjuvanted pandemic influenza H1N1 vaccine provides early and long term protection in health care workers. Vaccine 2010; 29:266-73; PMID: 21034828; DOI: 10.1016/j.vaccine.2010.10.038.
14. Shoji Y, Chichester JA, Bi H, Musiychuk K, de la Rosa P, Goldschmidt L, et al. Plant-expressed HA as a seasonal influenza vaccine candidate. Vaccine 2008; 26:2930-4; PMID: 18440103; DOI: 10.1016/j.vaccine.2008.03.045.
15. Shoji Y, Farrance CE, Bi H, Shamloul M, Green B, Manceva S, et al. Immunogenicity of hemagglutinin from A/Bar-headed Goose/Qinghai/1A/05 and A/Anhui/1/05 strains of H5N1 influenza viruses produced in Nicotiana benthamiana plants. Vaccine 2009; 27:3467-70; PMID: 19200814; DOI: 10.1016/j.vaccine.2009. 01.051.
16. Shoji Y, Bi H, Musiychuk K, Rhee A, Horsey A, Roy G, et al. Plant-derived hemagglutinin protects ferrets against challenge infection with the A/Indonesia/05/05 strain of avian influenza. Vaccine 2009; 27:1087-92; PMID: 19100806; DOI: 10.1016/j.vaccine.2008.11.108.
17. Mett V, Musiychuk K, Bi H, Farrance CE, Horsey A, Ugulava N, et al. A plant-produced influenza subunit vaccine protects ferrets against virus challenge. Influenza Other Respi Viruses 2008; 2:33-40; PMID: 19453491; DOI: 10.1111/j.1750-2659.2008.00037.x.
18. Cox RJ, Brokstad KA, Zuckerman MA, Wood JM, Haaheim LR, Oxford JS. An early humoral immune response in peripheral blood following parenteral inactivated influenza vaccination. Vaccine 1994; 12:993-9; PMID: 7975853; DOI: 10.1016/0264-410X(94)90334-4.
19. Cox RJ, Madhun AS, Hauge S, Sjursen H, Major D, Kuhne M, et al. A phase I clinical trial of a PER.C6 cell grown influenza H7 virus vaccine. Vaccine 2009; 27:1889-97; PMID: 19368768; DOI: 10.1016/j.vaccine.2009.01.116.
20. Moris P, van der Most R, Leroux-Roels I, Clement F, Dramé M, Hanon E, et al. H5N1 influenza vaccine formulated with AS03 A induces strong cross-reactive and polyfunctional CD4 T-cell responses. J Clin Immunol 2011; 31:443-54; PMID: 21174144; DOI: 10.1007/s10875-010-9490-6.
21. Roman F, Clément F, Dewé W, Walravens K, Maes C, Willekens J, et al. Effect on cellular and humoral immune responses of the AS03 adjuvant system in an A/H1N1/2009 influenza virus vaccine administered to adults during two randomized controlled trials. Clin Vaccine Immunol 2011; 18:835-43; PMID: 21450978; DOI: 10.1128/CVI.00480-10.
22. Seder RA, Darrah PA, Roederer M. T-cell quality in memory and protection: implications for vaccine design. Nat Rev Immunol 2008; 8:247-58; PMID: 18323851; DOI: 10.1038/nri2274.
23. Darrah PA, Patel DT, De Luca PM, Lindsay RWB, Davey DF, Flynn BJ, et al. Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat Med 2007; 13:843-50; PMID: 17558415; DOI: 10.1038/nm1592.
24. Forbes EK, Sander C, Ronan EO, McShane H, Hill AVS, Beverley PCL, et al. Multifunctional, high-level cytokine-producing Th1 cells in the lung, but not spleen, correlate with protection against Mycobacterium tuberculosis aerosol challenge in mice. J Immunol 2008; 181:4955-64; PMID: 18802099.
25. Madhun AS, Haaheim LR, Nilsen MV, Cox RJ. Intramuscular Matrix-M-adjuvanted virosomal H5N1 vaccine induces high frequencies of multifunctional Th1 CD4+ cells and strong antibody responses in mice. Vaccine 2009; 27:7367-76; PMID: 19781678; DOI: 10.1016/j.vaccine.2009.09.044.
26. Madhun AS, Haaheim LR, Nøstbakken JK, Ebensen T, Chichester J, Yusibov V, et al. Intranasal c-di-GMP-adjuvanted plantderived H5 influenza vaccine induces multifunctional Th1 CD4+ cells and strong mucosal and systemic antibody responses in mice. Vaccine 2011; 29:4973-82; PMID: 21600260; DOI: 10.1016/j.vaccine.2011.04.094.
27. Pedersen G, Halstensen A, Sjursen H, Naess A, Kristoffersen EK, Cox RJ. Pandemic influenza vaccination elicits influenzaspecific CD4+ Th1-cell responses in hypogammaglobulinaemic patients: four case reports. Scand J Immunol 2011; 74:210-8; PMID: 21438900; DOI: 10.1111/j.1365-3083.2011.02561.x.
28. D'Aoust M-A, Lavoie P-O, Couture MM-J, Trépanier S, Guay J-M, Dargis M, et al. Influenza virus-like particles produced by transient expression in Nicotiana benthamiana induce a protective immune response against a lethal viral challenge in mice. Plant Biotechnol J 2008; 6:930-40; PMID: 19076615; DOI: 10.1111/j.1467-7652.2008.00384.x.
29. Landry N, Ward BJ, Trépanier S, Montomoli E, Dargis M, Lapini G, et al. Preclinical and clinical development of plant-made virus-like particle vaccine against avian H5N1 influenza. PLoS One 2010; 5:e15559; PMID: 21203523; DOI: 10.1371/journal.pone.0015559.
30. Chu DW-S, Hwang S-J, Lim FS, Oh HML, Thongcharoen P, Yang P-C, et al. Immunogenicity and tolerability of an AS03(A)- adjuvanted prepandemic influenza vaccine: a phase III study in a large population of Asian adults. Vaccine 2009; 27:7428-35; PMID: 19683087; DOI: 10.1016/j.vaccine.2009.07.102.
31. Roman F, Vaman T, Gerlach B, Markendorf A, Gillard P, Devaster J-M. Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without AS03A-adjuvant: preliminary report of an observer-blind, randomised trial. Vaccine 2010; 28:1740-5; PMID: 20034605; DOI: 10.1016/j.vaccine.2009.12.014.
32. Lund JM, Alexopoulou L, Sato A, Karow M, Adams NC, Gale NW, et al. Recognition of single-stranded RNA viruses by Tolllike receptor 7. Proc Natl Acad Sci U S A 2004; 101:5598-603; PMID: 15034168; DOI: 10.1073/pnas.0400937101.
33. Diebold SS, Kaisho T, Hemmi H, Akira S, Reis e Sousa C. Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science 2004; 303:1529-31; PMID: 14976261; DOI: 10.1126/science.1093616.
34. Dupuis M, Denis-Mize K, LaBarbara A, Peters W, Charo IF, McDonald DM, et al. Immunization with the adjuvant MF59 induces macrophage trafficking and apoptosis. Eur J Immunol 2001; 31:2910-8; PMID: 11592066; DOI: 10.1002/1521- 4141(2001010)31:10<2910::AID-IMMU2910>3.0.CO;2-3.
35. Seubert A, Monaci E, Pizza M, O'Hagan DT, Wack A. The adjuvants aluminum hydroxide and MF59 induce monocyte and granulocyte chemoattractants and enhance monocyte differentiation toward dendritic cells. J Immunol 2008; 180:5402-12; PMID: 18390722.
36. Mosca F, Tritto E, Muzzi A, Monaci E, Bagnoli F, Iavarone C, et al. Molecular and cellular signatures of human vaccine adjuvants. Proc Natl Acad Sci U S A 2008; 105:10501-6; PMID: 18650390; DOI: 10.1073/pnas.0804699105.
37. Morel S, Didierlaurent A, Bourguignon P, Delhaye S, Baras B, Jacob V, et al. Adjuvant System AS03 containing α-tocopherol modulates innate immune response and leads to improved adaptive immunity. Vaccine 2011; 29:2461-73; PMID: 21256188; DOI: 10.1016/j.vaccine.2011.01.011.
38. Galli G, Medini D, Borgogni E, Zedda L, Bardelli M, Malzone C, et al. Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts long-term persistence of protective antibody levels. Proc Natl Acad Sci U S A 2009; 106:3877-82; PMID: 19237568; DOI: 10.1073/pnas.0813390106.
39. Stephenson I, Bugarini R, Nicholson KG, Podda A, Wood JM, Zambon MC, et al. Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a potential priming strategy. J Infect Dis 2005; 191:1210-5; PMID: 15776364; DOI: 10.1086/428948.
40. Leroux-Roels I, Borkowski A, Vanwolleghem T, Dramé M, Clement F, Hons E, et al. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet 2007; 370:580-9; PMID: 17707753; DOI: 10.1016/S0140-6736(07)61297-5.
41. Bernstein DI, Edwards KM, Dekker CL, Belshe R, Talbot HKB, Graham IL, et al. Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults. J Infect Dis 2008; 197:667-75; PMID: 18260764; DOI: 10.1086/527489.
42. Levie K, Leroux-Roels I, Hoppenbrouwers K, Kervyn A-D, Vandermeulen C, Forgus S, et al. An adjuvanted, low-dose, pandemic influenza A (H5N1) vaccine candidate is safe, immunogenic, and induces cross-reactive immune responses in healthy adults. J Infect Dis 2008; 198:642-9; PMID: 18576945; DOI: 10.1086/590913.
43. Cox RJ, Pedersen G, Madhun AS, Svindland S, Sævik M, Breakwell L, et al. Evaluation of a virosomal H5N1 vaccine formulated with Matrix M™ adjuvant in a phase I clinical trial. Vaccine 2011; 29:8049-59; PMID: 21864624; DOI: 10.1016/j.vaccine.2011.08.042.
44. Karaolis DKR, Means TK, Yang D, Takahashi M, Yoshimura T, Muraille E, et al. Bacterial c-di-GMP is an immunostimulatory molecule. J Immunol 2007; 178:2171-81; PMID: 17277122.
45. Chen W, Kuolee R, Yan H. The potential of 3′,5′-cyclic diguanylic acid (c-di-GMP) as an effective vaccine adjuvant. Vaccine 2010; 28:3080-5; PMID: 20197136; DOI: 10.1016/j.vaccine.2010.02.081.
46. Schild GC, Pereira MS, Chakraverty P. Single-radial-hemolysis: a new method for the assay of antibody to influenza haemagglutinin. Applications for diagnosis and seroepidemiologic surveillance of influenza. Bull World Health Organ 1975; 52:43- 50; PMID: 1082381.
47. Brokstad KA, Cox RJ, Olofsson J, Jonsson R, Haaheim LR. Parenteral influenza vaccination induces a rapid systemic and local immune response. J Infect Dis 1995; 171:198-203; PMID: 7798664; DOI: 10.1093/infdis/171.1.198.
48. Duvall MG, Precopio ML, Ambrozak DA, Jaye A, McMichael AJ, Whittle HC, et al. Polyfunctional T cell responses are a hallmark of HIV-2 infection. Eur J Immunol 2008; 38:350-63; PMID: 18200635; DOI: 10.1002/eji.200737768.